Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Description:
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).
Sponsor:
University of Alberta
Contacts:
Jonathan Abele, MD (Principal Investigator)jabele@ualberta.ca
780-407-6907
Government Study Link:
NCT04888481 - Click here to see study onClinicalTrials.gov
